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tTATE-OF-THE-ART PAPER455Minimally-Invasive Cardiac Valve Surgeryan D. Schmitto, Suyog A. Mokashi, Lawrence H. Cohn
inimally-invasive cardiac valve surgery is not defined as a specific procedure but rather a
hilosophy of avoiding a full sternotomy and cardiopulmonary bypass support. In this state-
f-the-art paper, Schmitto and colleagues review the history of minimally-invasive cardiac
alve surgery and the risks and benefits of different strategies. There is promising data from
ingle-center, nonrandomized, historical-control trials regarding mortality rates and other
omplications; most studies have found higher patient satisfaction. However, the authors
aution that optimism for these procedures must be balanced against the proven long-term
uccess of traditional cardiac surgery. Surgeons performing minimally-invasive cardiac valve
urgery should be experienced in both standard and minimally-invasive approaches and be
iligent in evaluating their results.CLINICAL RESEARCH NTERVENTIONAL CARDIOLOGY463Eptifibatide Noninferior to Abciximab for Primary PCI in a Randomized Trialwe Zeymer, Alain Margenet, Michael Haude, Christoph Bode, Jean-Marc Lablanche, Hubertus Heuer,
olf Schröder, Stefan Kropff, Ryad Bourkaib, Norbert Banik, Ralf Zahn, Emmanuel Teiger
he glycoprotein (GP) IIb/IIIa receptor inhibitor abciximab has been shown to reduce
schemic complications and improve clinical outcomes in ST-segment elevation myocardial
nfarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI),
ut it has never been compared to the small molecule GP IIb/IIIa receptor inhibitor
ptifibatide. Zeymer and colleagues randomized 427 STEMI patients to eptifibatide or
bciximab. There was no difference in the rate of the primary end point ST-segment
esolution 60 min after PCI. There were no significant differences in mortality, target vessel
evascularization, stroke, or Thrombolysis In Myocardial Infarction major bleeding
omplications, but the rate of reinfarction was lower with eptifibatide. This study suggests
hat eptifibatide and abciximab are equally effective as an adjunct to primary PCI.(continued on page A-20)
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ENTERVENTIONAL CARDIOLOGY470Eptifibatide Noninferior to Abciximab for Primary PCI in a Registry Reviewxel Åkerblom, Stefan K. James, Michail Koutouzis, Bo Lagerqvist, Ulf Stenestrand,
odil Svennblad, Jonas Oldgren
kerblom and colleagues reviewed data from almost 12,000 ST-segment elevation myocardial
nfarction (STEMI) patients in Sweden that underwent primary percutaneous coronary
ntervention (PCI) and received either eptifibatide or abciximab using the SCAAR (Swedish
oronary Angiography and Angioplasty Registry). The combined end point of death or
yocardial infarction during 1 year of follow-up occurred in 15% of eptifibatide-treated
atients and in 16% of abciximab-treated patients. This difference remained nonsignificant
fter multivariable adjustment. This large registry study suggests that eptifibatide is noninferior to
bciximab and supports the use of either drug in STEMI patients undergoing primary PCI.ditorial Comment: Peter B. Berger, p. 476ORONARY ARTERY DISEASE479Number of Copies of Variant 9p21 Predicts Severity of CADonny Dandona, Alexandre F. R. Stewart, Li Chen, Kathryn Williams, Derek So, Ed O’Brien,
hristopher Glover, Michel LeMay, Olivia Assogba, Lan Vo, Yan Qing Wang, Marino Labinaz,
eorge A. Wells, Ruth McPherson, Robert Roberts
common genetic variation in 9p21 has been linked to the risk of coronary artery disease
CAD), but the pathologic mechanism has not been elucidated. Dandona and colleagues
enotyped subjects with angiographically-proven CAD for the 9p21 variant. Those
omozygous for the 9p21 risk allele had a 2-fold higher risk for having 3-vessel disease at
naugural catheterization when compared with those with 2 copies of the nonrisk genotype.
omozygotes for the risk allele were also more likely to have left main trunk disease and
igher Gensini and Duke prognostic scores. These results not only confirm the link between
p21 and CAD, but also suggest that these lesions may be less likely to rupture because the
atients did not present until they had severe CAD.
ditorial Comment: Jeffrey L. Anderson, Benjamin D. Horne, p. 487(continued on page A-21)
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EARDIAC SURGERY490The Spectrum of Risk for Patients Enrolled in the STICH Trialobert H. Jones, Harvey White, Eric J. Velazquez, Linda K. Shaw, Ricardo Pietrobon, Julio A. Panza,
obert O. Bonow, George Sopko, Christopher M. O’Connor, Jean-Lucien Rouleau
he international STICH (Surgical Treatment for Ischemic Heart Failure) trial had a
omplex study design and relied on the clinical judgment of the enrolling physicians to
nsure that the potential benefits and risks to subjects were equivalent. This study sought to
etermine the overall risk profile of the cohort and whether it varied by country or site. The
uthors created a multivariable equation using the Duke Databank to predict the 5-year risk
f death without cardiac surgery. All trial subjects were then assigned to 1 of 32 risk-at-
andomization (RAR) groups created to share one-thirty-second of total predicted deaths.
ean RAR differences among countries did vary significantly; however, 76% of patients from
ountries enrolling lower-risk patients shared the same RAR group with patients from
ountries enrolling higher-risk patients. This study suggests that STICH randomized patients
re characterized by a continuous spectrum of risk without discordant dominance from any
ite or country.ARDIAC SURGERY499Comparison of Patients Enrolled in the STICH Trial to Those in the STS Databasearian Zembala, Robert E. Michler, Andrzej Rynkiewicz, Thao Huynh, Lilin She, Barbara Lubiszewska,
ames A. Hill, Ruzena Jandova, Francois Dagenais, Eric D. Peterson, Robert H. Jones
n a second article assessing the generalizability of the STICH (Surgical Treatment for
schemic Heart Failure) trial, Zembala and colleagues compared the patients enrolled in
he trial with patients enrolled in the Society of Thoracic Surgeons’ (STS) database. The
aseline clinical characteristics of trial subjects were compared with patients who underwent
oronary artery bypass grafting (CABG) and surgical ventricular reconstruction (SVR) but
ere not part of the trial. A total of 2,036 subjects were then divided into 32 risk-at-
andomization (RAR) groups based on a multivariable model. A total of 75% of the
ombined subjects were in the same RAR group, with only modest differences in baseline
haracteristics responsible for more low-risk STICH and more high-risk STS patients. The
TICH conclusion of no benefit from adding SVR to CABG applies to a broad spectrum of
ABG-eligible ischemic cardiomyopathy patients.
ditorial Comment: A. Laurie W. Shroyer, Joseph F. Collins, Frederick L. Grover, p. 508(continued on page A-22)
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510roof of Concept: Minimally-Invasive Implantation
of Living Tissue Engineered Heart Valvesörthe Schmidt, Petra E. Dijkman, Anita Driessen-Mol, Rene Stenger, Christine Mariani, Arja Puolakka,
arja Rissanen, Thorsten Deichmann, Bernhard Odermatt, Benedikt Weber, Maximilian Y. Emmert,
regor Zund, Frank P. T. Baaijens, Simon P. Hoerstrup
chmidt and colleagues note that the bioprosthetic valves currently used in minimally-invasive
alve replacement surgeries have limited durability. Through the use of tissue engineering,
alves were created with autologous cells on a biodegradable scaffold and then loaded onto a
elf-expanding nitinol stent. The tissue engineered heart valves (TEHVs) were then implanted as
ulmonary valve replacements in sheep using a minimally-invasive transapical approach.
he TEHV demonstrated in vivo functionality with mobile but thickened leaflets.
istology revealed layered neo-tissues with endothelialized surfaces. This study
emonstrates the feasibility of merging tissue engineering and minimally-invasive valve
eplacement technologies.
